In Denmark, Novozymes has announced it expects to turn a first-quarter sales loss into a growth of 2% to 3% for the full year. Although recent sales have fallen up to 9% in local currencies, market share gains and the launch of a new enzyme has encouraged the CFO, Benny Loft. “We’ll catch up with the 9% sales decline in the fist quarter, and will end the year with sales growth at the same level as the expected U.S. market growth,” he said.
Category: Fuels